Ntla stock zacks

NTLA Stock News - Fidelity Mar 27, 2020 · CAMBRIDGE, Mass., Feb. 27, 2020 -- Intellia Therapeutics, Inc. (NTLA), a leading genome editing company focused on developing curative therapeutics using CRISPR/Cas9 technology both in vivo and ex vivo, today reported operational highlights and financial results for the fourth quarter and year ended December 31, 2019. NTLA - Intellia Therapeutics, Inc. Summary, Stock Quote ...

Securities products and services offered to self-directed investors through ST Invest, LLC. Member FINRA / SIPC.ST Invest is a wholly owned subsidiary of StockTwits, Inc. Investing in securities products involves risk, including possible loss of principal. Please read important legal disclosures. Intellia Therapeutics Stock Quote: NTLA Stock News, Quotes ... Nov 08, 2019 · NTLA, Intellia Therapeutics - Stock quote performance, technical chart analysis, SmartSelect Ratings, Group Leaders and the latest company headlines Intellia Therapeutics (NASDAQ:NTLA) Stock Rating ... 4 days ago · Intellia Therapeutics (NASDAQ:NTLA) ‘s stock had its “buy” rating reissued by analysts at BTIG Research in a report released on Thursday, TipRanks reports. They currently have a $22.00 price objective on the stock. BTIG Research’s price objective would suggest a potential upside of 83.49% from the company’s current price.

Find the latest Intellia Therapeutics, Inc. (NTLA) stock quote, history, news and other vital information to help you with your stock trading and investing.

NTLA Stock Price, Forecast & News (Intellia Therapeutics) Intellia Therapeutics Inc (NASDAQ:NTLA) issued its quarterly earnings results on Thursday, February, 27th. The company reported ($0.57) earnings per share (EPS) for the quarter, missing the Zacks' consensus estimate of ($0.56) by $0.01. Implied Volatility Surging for Intellia (NTLA) Stock ... Feb 07, 2020 · Investors in Intellia Therapeutics, Inc. NTLA need to pay close attention to the stock based on moves in the options market lately. That is because the Feb 21, 2020 $17.50 Call had some of the NTLA Stock Quote - Intellia Therapeutics, Inc. Common ... Stock quote for Intellia Therapeutics, Inc. Common Stock Common Stock (NTLA) with real-time last sale and extended hours stock prices, company news, charts, and research at Nasdaq.

What's going on at Intellia Therapeutics (NASDAQ:NTLA)? View breaking news headlines for NTLA stock from trusted media outlets at MarketBeat.

NTLA Stock News - Fidelity Mar 27, 2020 · CAMBRIDGE, Mass., Feb. 27, 2020 -- Intellia Therapeutics, Inc. (NTLA), a leading genome editing company focused on developing curative therapeutics using CRISPR/Cas9 technology both in vivo and ex vivo, today reported operational highlights and financial results for the fourth quarter and year ended December 31, 2019.

NTLA - Intellia Thera CS Stock Price - Barchart.com

4 days ago · Intellia Therapeutics (NASDAQ:NTLA) ‘s stock had its “buy” rating reissued by analysts at BTIG Research in a report released on Thursday, TipRanks reports. They currently have a $22.00 price objective on the stock. BTIG Research’s price objective would suggest a potential upside of 83.49% from the company’s current price. Intellia Therapeutics (NASDAQ:NTLA) Rating Increased to ... Zacks Investment Research upgraded shares of Intellia Therapeutics (NASDAQ:NTLA) from a sell rating to a hold rating in a research report sent to investors on Thursday, Zacks.com reports. NTLA News Today (Intellia Therapeutics) | MarketBeat What's going on at Intellia Therapeutics (NASDAQ:NTLA)? View breaking news headlines for NTLA stock from trusted media outlets at MarketBeat.

Stock Analysis, Dividends, Split History. NTLA / Intellia Therapeutics, Inc. financial ratios include Market Cap, Enterprise Value, Book Value, Quick Ratio, Current 

Implied Volatility Surging for Intellia (NTLA) Stock Options Feb 07, 2020 · Investors in Intellia Therapeutics, Inc. NTLA need to pay close attention to the stock based on moves in the options market lately. That is because the Feb 21, 2020 $17.50 Call had some of the Intellia Therapeutics, Inc. (NTLA) Stock Price, Quote ...

Feb 19, 2020 (NTLA) Q4 Earnings Expected to Decline. Zacks Equity Research February 19, 2020. Trades from $1. NTLA: Get the latest Intellia Therapeutics stock price and detailed information Zacks 41d. Intellia Therapeutics Announces Fourth Quarter and Full-Year 2019  Intellia Therapeutics, Inc. NTLA:NASDAQ Trade NTLA stock for free with recommended broker TD Ameritrade. (NTLA) Reports Q4 Loss, Tops Revenue Estimates ZacksFeb 27, 2020; Intellia (NTLA) to Report Q4 Earnings: What's in Store? Wall Street analysts expect Intellia Therapeutics Inc (NASDAQ:NTLA) to report $23.98 million in sales for the current fiscal quarter, according to Zacks. Six analysts  Stock Analysis, Dividends, Split History. NTLA / Intellia Therapeutics, Inc. financial ratios include Market Cap, Enterprise Value, Book Value, Quick Ratio, Current  (NASDAQ:NTLA) has 154 institutional investors and shareholders that have filed 13D/G or 13F forms with the Securities Exchange Commission (SEC). These